Methods of administering anti-fibrotic therapy
AssigneeGenentech, Inc.
InventorsLin Pan, Dorothy Sze-Wing Cheung, Jeffrey Mark Harris, Indiana Strombom
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods of administering Compound I for treating fibrotic disorders, inflammatory disorders or autoimmune disorders.
Claims56
A method of administering Compound I to treat a subject suffering from a fibrotic disorder, an inflammatory disorder, or an autoimmune disorder, comprising administering a therapeutically effective amount of Compound I in combination with food.
A method of increasing drug bioavailability in Compound I therapy, comprising:
- administering to a subject a therapeutically effective amount of Compound I with food, wherein the bioavailability of Compound I is increased compared to the bioavailability of the same amount of Compound I administered without food.
A method for providing Compound I therapy to a subject, comprising providing a therapeutically effective amount of Compound I to the subject;
- and advising the subject not to take a gastric acid reducing agent concomitantly with Compound I.
A method for providing Compound I therapy, comprising administering a therapeutically effective amount of Compound I to a subject having an intra-gastric pH equal to or less than 4.
A method of providing Compound I therapy to a subject, comprising:
- evaluating the renal function of the subject;
- and
- administering a therapeutically effective amount of Compound I to the subject.
A method of providing an anti-fibrotic therapy to a subject, comprising:
- evaluating the renal function of the subject;
- advising the subject to not take Compound I;
- and
- providing anti-fibrotic therapy other than Compound I.
A kit comprising a pharmaceutical composition, prescribing information, and a container, wherein the pharmaceutical composition comprises a therapeutically effective amount of Compound I.
Dependencies are inferred from the claim text.